ScripBristol Myers Squibb is hopeful that it still has a chance to expand the label for Reblozyl (luspatercept-aamt) after a Phase III trial failed to meet the primary endpoint but met several secondary en
Pink SheetUpcoming federal spending reductions and resulting coverage losses in Medicaid could have a significant impact on patient access to drugs for HIV, cystic fibrosis and mental health, as well as treatme
ScripAt least officially, Bristol Myers Squibb and Pfizer’s are selling the anticlotting drug Eliquis (apixaban) directly to consumers to lower costs for patients, especially those who are uninsured, under
Pink SheetStakeholders believe that under the US Centers for Medicare and Medicaid Services’ current approach to implementing the Medicare price negotiation program for Part B physician-administered drugs, the